<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635672</url>
  </required_header>
  <id_info>
    <org_study_id>VNC-152-101</org_study_id>
    <secondary_id>2014-004808-30</secondary_id>
    <nct_id>NCT02635672</nct_id>
  </id_info>
  <brief_title>Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer</brief_title>
  <official_title>An Open-label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of VIP152 (BAY 1251152) in Patients With Advanced Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vincerx Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vincerx Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and&#xD;
      recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) in patients with solid tumors and&#xD;
      aggressive non-hodgkin's lymphoma (NHL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of DLT (Dose limit toxicity) of VIP152 (BAY1251152)</measure>
    <time_frame>End of Cycle 1 / Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of BAY1251152</measure>
    <time_frame>Cycle1 / Day 1 (C1D1), C1D2,C1D3, C1D4, C1D8C1D15, C1D16,C1D17,C1D18,C2D1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration versus time curve from zero to infinity after single (first) dose (AUC) of VIP152 (BAY1251152)</measure>
    <time_frame>C1D1, C1D2,C1D3, C1D4, C1D8,C1D15, C1D16,C1D17,C1D18,C2D1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to the last data point &gt; Lower limit of quantitation (LLOQ) [AUC(0-tlast)] of VIP152 (BAY1251152)</measure>
    <time_frame>C1D1, C1D2,C1D3, C1D4, C1D8,C1D15, C1D16,C1D17,C1D18,C2D1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed drug concentration in measured matrix after multiple dose administration during a dosage interval (Cmax,md) of BAY1251152</measure>
    <time_frame>C1D1, C1D2,C1D3, C1D4, C1D8,C1D15, C1D16,C1D17,C1D18,C2D1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to the last data point &gt; LLOQ after multiple dosing [AUC(0-tlast)md] of VIP152 (BAY1251152)</measure>
    <time_frame>C1D1, C1D2,C1D3, C1D4, C1D8,C1D15, C1D16,C1D17,C1D18,C2D1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152)</measure>
    <time_frame>C1D1, C1D2,C1D3, C1D4, C1D8,C1D15, C1D16,C1D17,C1D18,C2D1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure safety and tolarability</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response evaluation based on the response criteria as applicable (RECIST v1.1 criteria for solid tumors and revised Lugano Classification for aggressive NHL)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">107</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dose escalation of VIP152 (BAY 1251152) / PART 1 (Completed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigating VIP152 (BAY 1251152) in a dose escalation cohort in patients with solid tumors and aggressive NHL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion of VIP152 (BAY 1251152) / PART 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigating VIP152 (BAY 1251152) in a dose expansion cohort in patients with solid tumors and aggressive NHL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIP152 (BAY 1251152)</intervention_name>
    <description>The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles.</description>
    <arm_group_label>Dose escalation of VIP152 (BAY 1251152) / PART 1 (Completed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIP152 (BAY 1251152) 30 mg</intervention_name>
    <description>30 mg IV (30 minute infusion) fixed dose once weekly of a 21 day cycle.</description>
    <arm_group_label>Dose expansion of VIP152 (BAY 1251152) / PART 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged &gt;/=18 years&#xD;
&#xD;
          -  Patients with a histologically or cytologically confirmed solid tumor or aggressive&#xD;
             NHL who are refractory to or have exhausted all available therapies with MYC&#xD;
             expression or known C-MYC amplification/alterations&#xD;
&#xD;
          -  Adequate bone marrow, liver, and renal functions&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active clinically serious infections of events &gt; Grade 2&#xD;
&#xD;
          -  Subjects who have new or progressive brain or meningeal or spinal metastases.&#xD;
&#xD;
          -  Anticancer chemotherapy or immunotherapy during the study or within 1 weeks prior to&#xD;
             the first dose of study drug&#xD;
&#xD;
          -  Major surgery or significant trauma within 4 weeks before the first dose of study drug&#xD;
&#xD;
          -  Allogeneic bone marrow transplant or stem cell rescue within 4 months before first&#xD;
             dose of study drug; patients must have completed immunosuppressive therapy before&#xD;
             enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincerx Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Vincerx Pharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincerx Clinical Trials Contact</last_name>
    <phone>(+) 1-650-800-6676</phone>
    <email>clinicaltrials@vincerx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>https://www.fda.gov/drugs/drug-safety-and-availability</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors</keyword>
  <keyword>Aggressive non-hodgkin's lymphoma (NHL)</keyword>
  <keyword>Advanced Ovarian</keyword>
  <keyword>Triple Negative Breast</keyword>
  <keyword>DHL</keyword>
  <keyword>Double-Hit Lymphoma</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Blastoid Mantle Cell</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>MYC overexpression</keyword>
  <keyword>MYC amplification</keyword>
  <keyword>MYC translocation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

